The glacial pace of change in mechanistic but essential areas of clinical trials undermines the biopharma industry's claims of progress and compassion.

Ozempic cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20% in a trial of patients with type 2 diabetes and chronic kidney disease.

Critics argue that a pattern of inconsistencies in the MDMA clinical trial data and other shortcomings compromise the integrity of the studies.

Cytokinetics did a deal with Royalty Pharma, the biotech firm that has become a huge success by buying up small shares of other companies’ drugs.

Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalittle campus. I’m not a coffee drinker, but who needs caffeine when you’ve got the raw adr

The Biotechnology Innovation Organization on Monday announced 30 layoffs that are part of a restructuring.

Sen. Bernie Sanders is testing the limits of the powers of a Senate chairman with little hope of advancing his drug-pricing agenda legislatively.

HHS's proposal for addressing the climate crisis serves as an example of what historian and philosopher Hannah Arendt defined as the "banality of evil."

The FDA approved an innovative treatment from Amgen for patients with small cell lung cancer who have exhausted all other options.

Data from wearables can be powerful but they're not useful to doctors yet, experts said at the #STATBreakthrough Summit in San Francisco.

Speaking at #STATBreakthrough Summit, Microsoft’s Peter Lee talked about how ChatGPT and generative AI still have tricky blindspots.

Roche disclosed that its recently acquired experimental obesity medication helped people lose a significant amount of weight in a Phase 1 trial.

Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.

Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.

Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.

A new study in JAMA identifies a genetic variant commonly found in people of West African descent that raises a type of cardiovascular disease risk.

When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.

More and more studies show that alcohol isn't healthy after all. Dietary guidelines are up for revision in 2025, and already, there's debate over research and industry influence.

Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.

Pfizer agreed to settle more than 10,000 cases accusing it of hiding cancer risks of its Zantac heartburn drug.

Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.

A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.

Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.

The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.

A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.